Skip to main
PFE
PFE logo

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 31 analyst ratings
Hold
Strong Buy 23%
Buy 13%
Hold 61%
Sell 3%
Strong Sell 0%

Bulls say

Pfizer's stock outlook remains positive due to its robust annual sales of approximately $60 billion, primarily driven by its successful prescription drugs and vaccines. The company's strong portfolio, including top-selling products like Prevnar 13, Ibrance, and Eliquis, has been complemented by significant contributions from international markets, which account for 40% of total sales, particularly from emerging economies. Additionally, initiatives such as the Low-Income Subsidy eligibility expansion could enhance patient access and stabilize prescription volumes, further solidifying Pfizer's financial position.

Bears say

Pfizer is facing a negative outlook due to anticipated higher gross-to-net adjustments on its premium medicines, particularly Vyndaqel and Ibrance, which will impact revenue recognition in the early part of the year. The company also struggles with the market's potential underestimation of these adjustments, leading to uncertainty in financial projections. Additionally, the heavy reliance on prescription drugs and vaccines for revenue might exacerbate vulnerabilities in a competitive and evolving pharmaceutical landscape.

Pfizer (PFE) has been analyzed by 31 analysts, with a consensus rating of Hold. 23% of analysts recommend a Strong Buy, 13% recommend Buy, 61% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Hold based on their latest research and market trends.

According to 31 analysts, Pfizer (PFE) has a Hold consensus rating as of Sep 8, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.06, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.06, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.